The condition diffuse panbronchiolitis is named, in Japan.

It was recognized as a distinct new disease in the early 1960s, and was formally named diffuse panbronchiolitis in 1969.

The presence of HLA-Bw54 increases the risk of diffuse panbronchiolitis 13.3-fold.

Diffuse panbronchiolitis (DPB) is an inflammatory lung disease of unknown cause.

In 1969, the name "diffuse panbronchiolitis" was introduced to distinguish it from chronic bronchitis, emphysema, alveolitis, and other obstructive lung disease with inflammation.

The macrolide antibiotics erythromycin, clarithromycin, and roxithromycin have proven to be an effective long-term treatment for the idiopathic, Asian-prevalent lung disease diffuse panbronchiolitis (DPB).